chemistry

                                     Chemistry CV

Robert A. Izydore
Professor of Chemistry, North Carolina Central University

Education
Pennsylvania State University; B.S. in Chemistry.
Duquesne University; PhD. in Organic Chemistry with minor in Analytical Inorganic Chemistry.
Duke University; Postdoctoral Research Associate in Organic Chemistry.

Honors
North Carolina Central University Outstanding Researcher Award; August, 1988; April, 2002
Nominated by NCCU for the UNC System O. Max Gardner Award, 1999
Who's Who Among America's Teachers, selected in 1996, 2004, 2005

U. S. Patents
"Method for the Control of Hyperlipidemia, 1, 2, 4 Triazolidine 3,5 diones, 1,3,5 triazabicyclo[3.1.0]
hexane 2,4 diones, 1,3,5 triazine 2,4 diones), Robert A. Izydore and Iris H. Hall, U.S. Patent No.
4,866,058, issued September, 1989.

"Compositions for the Control of Hyperlipidemia using N Substituted Isoxazolidine 3,5 diones",
Robert A. Izydore and Iris H. Hall, U.S. Patent No. 4,946,963, issued August, 1990.

"Compositions and Method of Treatment for the Control of Hyperlipidemia (Isoxazolidine-3,5 diones)",
Robert A. Izydore and Iris H. Hall, U.S. Patent No. 4,999,366, issued March, 1991. Licensed to Japan
Tobacco Inc., $500,000, July, 1998.

"Compositions for the Control of Hyperlipidemia (1,3,5 Triazabicyclo[3.1.0]-2,4 diones]", Robert A.
Izydore and Iris H. Hall, U.S. Patent No. 5,034,528, issued July, 1991.

"Compositions for the Control of Hyperlipidemia (1,2,4 Triazolidine 3,5 diones, 1,3,5 Triazine 2,4
diones)", Robert A. Izydore and Iris H. Hall, U. S. Patent No. 5,192,761, issued March, 1993

Publications
"Scientific Instrumentation in Chemistry, Biology, and Physics. An Interdisciplanary Approach," R. A.
Izydore, C. R. Jones, M. M. Townes, and H. E. Amman, J. Chem. Ed., 60, 1065 (1983).

"Decomposition Reactions of a cis Diacyl Diimide. 4 Phenyl 1,2 4 triazoline 3,5 dione," R. A. Izydore, H.
E. Johnson, and R. T. Horton, J. Org. Chem., 50, 4589 (1985).

"Reaction of Acetone Oxime with Dialkylmalonyl Chlorides. Synthesis of 2 Alkenylisoxazolidine 3,5
diones and 2,2 bis (2 (4,4 Diethylisoxazolidine 3,5 dione))propanes," R. A. Izydore, R. G. Davis, and N.
W. Clements, J. Heterocyclic Chem., 24, 1521 (1987).

"Reaction of Diazoalkanes with 4 Substituted 4H 1,2,4 Triazole 3,5(4H) diones," R. A. Izydore, J. A.
Mitchell, J. J. Chapman, R. Cummings, G. T. Jones, and C. D. McIver, Journal of the Chemical Society,
Perkin Transactions 2, 1415 (1988).

"Reaction of 4,4 Diethyl 3,5 pyrazolidinedione with Carboxylic Acid Anhydrides. N Acylation vs
O Acylation," R. A. Izydore, J. A. Bernal Ramirez, and P. Singh, J. Org. Chem., 55, 3761 (1990).

"Hypolipidemic Activity of Benzohydroxamic Acids and Dibenzohydroxamic Acids in Rodents," R. A.
Izydore, M. L. Debnath, T. Woodard, O. T. Wong, and I. H. Hall, Research Communications in Chemical
Pathology and Pharmacology, 70, 307 (1990).

"Hypolipidemic Activity of Aliphatic Dicarboxylic Acids in Rodents," R. A. Izydore and I. H. Hall, Acta
Pharmaceutica Nordica, 3, 141 (1991).

"Potential Aldose Reductase Inhibitors: 1,2,4 Triazolidine 3,5 diones and 2-(3,4,5-Trimethoxy-
benzoyl) 4,4 diethyl 3,5 isoxazolidinedione," I. H. Hall, R. A. Izydore, R. Simlot, and O. T. Wong,
Experimentia, 48, 383 (1992).

"The Antineoplastic and Cytotoxicity of Benzohydroxamic Acids and Related Derivatives," I. H. Hall, R.
A. Izydore, E. S. Hall, D. L. Daniels, M. C. Miller, M. L. Debnath, and T. Woodard, Anti Cancer Drugs, 33,
273 (1992).

"Efects of Isoxazolidine or Triazolidine on Rat Serum Lipids In Vivo and LDL and HDL Binding and
Degradation in Human and Rodent Cultured Cells In Vitro," I. H. Hall, O. T. Wong, R. Simlot, and R. A.
Izydore, Research Communications in Chemical Pathology and Pharmacology, 77, 327 (1992).

"Antineoplastic Activities and Cytotoxicity of 1 Acyl and 1,2 Diacyl 1,2,4 triazolidine 3,5 diones in
Murine and Human Tissue Culture Cells," I. H. Hall, O. T. Wong, R. Simlot, Merrill C. Miller, III, and R.
A. Izydore, Anticancer Research, 12, 1355-1362 (1992).

"Hypolipidemic Activity of 6 Alkoxycarbonyl 3 aryl 1,3,5 triazabicyclo[3.1.0]hexane 2,4 diones and   2
Alkoxycarbonyl 5 aryl 1,3,5 triazine 4,6(1H,5H) diones in Rodents," Robert A. Izydore, O. T. Wong, and
Iris H. Hall, Lipids, 28, 223-229 (1993).

"Synthesis and Hypolipidemic Activity of 4 Substituted 1 Acyl 1,2,4 triazolidine 3,5 diones in   Rodents,"
Ruprendra Simlot, Robert A. Izydore, O. T. Wong, and Iris H. Hall, Journal of Pharmaceutical Sciences,
82, 408 (1993).

"Hypolipidemic Activity of 1 Acyl and 1,2 Diacyl 3,5 pyrazolidinediones in Rodents," R. A. Izydore, J. A.
Bernal Ramirez, W. A. Okwisa, O. T. Wong, L. V. Yarborough, and Iris H. Hall, Pharmazie, 48, 111 (1993).

"The Hypolipidemic Effects of 1 Acetyl 4 phenyl 1,2,4 triazolidine 3,5 dione in Rodents," Iris H. Hall,
Ruprenda Simlot, Patricia Day, O. T. Wong, Hamby ElSourady, and Robert A. Izydore, Pharmaceutical
Research, 10, 1206 1211 (1993).

"Hypolipidemic Activity of 4 Substituted 1,2 Diacyl 1,2,4 triazolidine 3,5 diones in Rodents," Ruprendra
Simlot, Robert A. Izydore, O. T. Wong, and Iris H. Hall, Journal of Pharmaceutical Sciences, 83, 367 371
(1994).

"Disposition of the Pharmacologically Active Compound [1 14C Acetyl] 1 acetyl 4 phenyl 1,2,4
triazolidine 3,5-dione in CF1 Mice," R. P. Shrewsbury, S. D. Wyrick, A. L. Elkins, R. A. Izydore, S.Y.
Chen, M. C. Miller III, B. R. Burnham, and Iris H. Hall, Drug Investigations, 7, 275 281 (1994).

"Investigation of 3,5 Isoxazolidinediones as Hypolipidemic Agents in Rodents," R. A. Izydore, I. H. Hall,
T. Woodard, D. L. Daniels, M. L. Debnath, R. Simlot, O. T. Wong, and H. Elsourady, Pharmaceutical
Research, 21, 24 38 (1995).

"Structure Activity Relationships of 4 Substituted 1 Acyl and 1,2 Diacyl 1,2,4 triazolidine 3,5 diones as
Anti inflammatory Agents in Rodents," Iris H. Hall, Ruprendra Simlot, and Robert A. Izydore, Arch.
Pharm, 328, 5 10 (1995).

"The Cytotoxic Activity of 1 Acyl and 1,2 Diacyl 3,5 pyrazolidinediones," Iris H. Hall, Robert A. Izydore,
Tywanna S. Vital, S. Y. Chen, Merrill C. Miller, III, Juan A. Bernal Ramirez, Winfred A. Okwisa, and K. G.
Rajendran, Anticancer Drugs, 15, 199-204 (1995).

"1,2 Diacetyl 4 phenyl 1,2,4 triazolidine 3,5 dione," Phirtu Singh and Robert A. Izydore, Acta
Crystallographica Section C, C52, 1817-1820 (1996).

"Structure and Conformations of Monoacyl and Diacyl 1,2,4-Triazolidine-3,5-diones," Robert A.
Izydore, Anthony A. Ribeiro, and Iris H. Hall, Journal of Organic Chemistry, 61, 3733-3737 (1996).

"Synthesis and Cytotoxic Action of 3,5-Isoxazolidinediones and 2-Isoxazoline-5-ones in Murine and
Human Tumors," Iris H. Hall, Robert A. Izydore, Xaioming Zhou, Dwayne L.Daniels, Tyrone Woodard,
Manik L. Debnath, Elaine Tse, and Rosallah A. Muhammad, Archiv der Pharmazie, 330, 67-73 (1997).

"Hypolipidemic Triazolidine-3,5-diones, 3,5-Pyrazolidinediones, 3,5-Isoxazolidinediones, 1,3,5-
Triazabicyclo[3.1.0]hexane-2,4-diones as HMG-CoA Reductase, ACAT, GPAT, and PP Inhibitors and
NCEH Activators," I. H. Hall, R. A. Izydore, Betsy Jo Barnes, Fei Wang, Amy E. Warren, Cheryl R.
Barnes, Dwayne E. Coleman, Camille White, and Felicia E. Frazier, Recent Research Developments in
Lipids Research, 1, 297-303 (1997).

"The Cytotoxic Action of 1,3,5-Triazabicyclo[3.1.0]hexane-2,4-diones and 1,3,5-Triazine-4,6-(1H,5H)-
diones in Murine and Human Tumor Cells," I. H. Hall, K. Taylor, R. A. Izydore, D. E. Coleman, J. A.
Mitchell, and R. Cummings, Die Pharmazie, 53, 398-405 (1998).

The Effects of Benzohydroxamic Acids on L1210 Lymphoid Leukemia Cell Nucleic Acid Metabolism,”
Iris H. Hall, Karen Taylor, Robert A. Izydore, and Dwayne L. Daniels, Die Pharmacy, 53, 794-799 (1998).

“Cytotoxicity and Mode of Action of Aliphatic Dicarboxylic Acids in L1210 Lymphocytic Leukemia
Cells,” Iris H. Hall, Robert A. Izydore, Amy E. Warren, and Cheryl R. Barnes, Anticancer Research, 19,
205-212 (1999).

“Synthesis and Cytotoxic Action of 1-Oxoalkyl and 1,2-Dioxoalkyl-1,2,4-Triazolidine-3,5-diones in

Murine and Human Tissue Cultured Cells,” Christopher MacLauchlin, Iris H. Hall, and Robert A. Izydore,
Archiv. Pharmazie Med. Chem. 332, 225-232 (1999).

“Selective Inhibition of Human Molt-4 Leukemia Type II Inosine 5'-Monophosphate Dehydrogenase by
the 1,5-Diazabicyclo[3.1.0]hexane-2,4-diones,” Betsy J. Barnes, Ann E. Eakin, Robert A. Izydore, and
Iris H. Hall, Biochemistry, 39, 13641-13650 (2000).

“Implications of Selective Type II IMP Dehydrogenase (IMPDH) Inhibition by the 6-Ethoxycarbonyl-
3,3-disubstituted-1,5-diazabicyclo[3.1.0]-hexane-2,4-diones on Tumor Cell Death,” Betsy J. Barnes, Ann
E. Eakin, Robert A. Izydore and Iris H. Hall, Biochemical Pharmacology, 62, 91-100 (2001).

“Cytotoxicity of 2-Ethenyl-2,3-dihydrophthalazine-1,4-diones in Murine and Human Tumor Cultured
Cells”, I. H. Hall, D. W. Covington, J. R. Wheaton, R. A. Izydore, and Xiaoming Zhou, Pharmazie, 56, 168-
174 (2001).

“The Cytotoxicity of 1-(1-Phenylalkylideneamino)-2,4-azetidinediones and their Mode of Action in
Human and Murine Tumor Cells”, Robert A. Izydore, Yun Zhang, Xiaoming Zhou, Amy E. Warren,
Jessica R. Wheaton , and Iris H. Hall, Anticancer Research, 21, 157-165 (2001).

“Tmolt4 Leukemic Type II Isoform of IMP Dehydrogenase as a Target for 1,2,4-Triazolidine-3,5-diones,
1-(1-(3-Methylphenyl)ethylideneamino)-4,4-diethyl-3,5-azetidinediones, 3,5-Isoxazolidinediones and
4,4-Disubstituted 3,5-Pyrazolidinediones,” Iris H. Hall, Betsy J. Barnes, E. Stacey Ward, Jessica R.
Wheaton, Amy E. Warren, and Robert A. Izydore, Archives der Pharmazie Pharmazie Med. Chem., 334,
109 116, (2001).

“Specific Inhibition of Type II Inosine Monophosphate Dehydrogenase Activity of Tmolt4 T Cell Human
Leukaemia Cells by 3-Methoxy and di-Benzohydroxamic Acids, Maleic Hydrazide and Malonic Acids,” I.
H. Hall, B. J. Barnes, E. S. Ward, J. R. Wheaton, and R. A. Izydore, Journal of Pharmacy and
Pharmacology, 53, 749-755 (2001).

“Specific Inhibition of Type II IMP Dehydrogenase Activity of Tmolt4 T Cell Human Leukemia Cells by
Benzohydroxamic and Aliphatic Dicarboxylic Acids,” I. H. Hall, B. J. Barnes*, J. H. Wheaton, and R. A.
Izydore, Pharmaceutical Science, in press.

“Cytotoxicity and Mode of Action of 1-(1-Cyclohexenyl) and 1-Unsubstituted 3,5-pyrazolidinediones in
Human Tmolt4 T cell Leukemic Cells ,” Betsy J. Barnes*, Robert A. Izydore, and Iris H. Hall, Anticancer
Research, 21, 1857-1868 (2001).

"Induction of Tmolt4 Leukemia Cell Death by 3,3 Disubstituted 1,5 Diazabicyclic[3.1.0]hexane 2,4
diones: Specificity for Type II IMP Dehydrogenase" Barnes, B. J., Izydore R. A., Eakin A. E. and I. H.
Hall, Journal of Pharmacology and Experimental Therapeutics, 298, 790-796 (2001).

" Mechanism of Action of the Antitumor Agents 6 Benozyl 3,3 disubstituted 1,5 diazabicyclo[3.1.0]-
hexane 2,4 diones: Potent Inhibitors of Human Type II Inosine 5' Monophosphate Dehydrogenase" B.
J. Barnes, R. A. Izydore, and I. H. Hall, Int'l J. Cancer, 94, 275-281 (2001).

“Analysis of the in vitro Inhibition of Murine and Human Tumor Cell Growth by Pyrazole Derivatives and
a Substituted Azabicyclo[3.1.0]hexane 2,4 dione,” Barnes, B.J., Izydore, R.A., and Hall, I. H., Anticancer
Res., 21, 2313-2322 (2001).

“Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a
substituted azabicyclo[3.1.0] hexane-2,4-dione,” Barnes, Betsy J.; Izydore, Robert A.; Hall, Iris H,
Anticancer Research, 21, 2313-2322 (2001).

“Reactions of Oximes With Dicarboxylic Acid Chlorides,” Izydore, Robert A., Jones, Joseph T., Swain,
Ira N., Davis, Ronda G., Daniels, Dwayne L., Spaulding, Sharnelle T., and Frazier, Felicia, Journal of
Organic Chemistry, in preparation.

Abstracts (National and International Meetings)
"The Synthesis of Bicyclic Diaziridine Compounds," R. A. Izydore and J. J. Chapman, Abstract of Papers,
175th National Meeting of the American Chemical Society, Anaheim,CA,April,1978; ORGN 114.

"A Mechanistic Study of the Decomposition of a cis Diacyl Diimide. 4 Phenyl 1,2,4 triazolidine 3,5
dione," R. A. Izydore, H. E. Johnson, and R. T. Horton, Abstract of Papers, 101'st National Meeting of the
American Chemical Society, Atlanta, GA, April, 1981; ORGN 178.

"Reaction of Acetone Oxime with Dicarboxylic Acid Chlorides," R. A. Izydore, R. G. Davis, and N. W.
Clements, Abstract of Papers, 183rd National Meeting of the American Chemical Society, Las Vegas, NV;
April, 1982; ORGN 174.

"Decomposition Reactions of a cis Diacyl Diimide. 4 Phenyl 1,2,4 Triazoline 3,5 dione," R. A. Izydore, H.
E. Johnson, and R. T. Horton, Abstract of Papers, 189th National Meeting of the American Chemical
Society, Miami Beach, FL, May, 1985; ORGN 116.

"Hypolipidemic Activity of Isoxazolidine 3,5 diones," R. A. Izydore and I. H. Hall, Abstract of Papers,
joint meeting of the 3'rd Chemical Congress of North America and the 195th ACS National Meeting in
Toronto, Ontario, Canada, June, 1988; MEDI 126.

"Synthesis and Hypolipidemic Activity of 1,2,4 Triazolidine 3,5 diones," Robert A. Izydore, Iris H. Hall,
"Hypolipidemic Activity of Benzohydroxamic Acids, Dibenzohydroxamic Acids, and Aliphatic
Dicarboxylic Acids," Division of Medicinal Chemistry, 201st National Meeting of the American Chemical
Society; Atlanta, Georgia, April, 1991; MEDI 121.

"Synthesis and Cytotoxicity of 3,5-Isoxozolidinediones and 2-Isoxazoline-5-ones in Murine and Human
Tissue Cultured Cell Lines," R. A. Izydore, I. H. Hall, X. Zhou, D. L. Daniels, T. Woodard, E. Tse, and
R. A. Muhammad, Division of Medicinal Chemistry, 213th National Meeting of the American Chemical
Society, San Francisco, California, April, 1997; MEDI 219.

“Synthesis and Cytotoxic Activity of 1,5-Diazabicyclo[3.1.0]hexan-2,4-diones as IMP Dehydrogenase
Inhibitors,” B. J. Barnes, I. H. Hall, and R. A. Izydore, 49th Southeastern Regional Meeting of the
American Chemical Society 1997 Southeastern; Roanoke, Virginia, November, 1997.

“Design of Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitors,” B. J. Barnes, I. H. Hall, and R.
A. Izydore, 50th Southeastern Regional Meeting of the American Chemical Society, Research Triangle
Park, North Carolina, November, 1998; Abstr. 89.

Robert A. Izydore, Xiaoming Zhou*, Yun Zhang*, Theresa M. Wallace*, and Iris H. Hall, “Synthesis of 1-
Ethylideneamino-3,3-disubstituted-2,4-azetidinediones as Potential Pharmacologically Active Agents,”
1998 National Minority Research Symposium, New York, New York, November, 1998.

“Specific Inhibition of Human Inosine 5'-Monophosphate Dehydrogenase (IMPDH) by the 1,5-
Diazabicyclo[3.1.0]hexane-2,4-diones Causes Pronounced Inhibition of Tumor Cell Growth,” B. J.
Barnes, R. A. Izydore, and I. H. Hall, Meeting of the American Cancer Society, Philadelphia,
Pennsylvania, April, 1999.

Research Grants
National Science Foundation-Research Initiation for Minority Institution Improvement: Grant Number
SER76-08661; Robert A. - Izydore, Principal Investigator, “Synthesis, Spectral Properties and Reactivity
of Diaziridine Compounds”; $20,000; 6/1/76-11/30/78.

Public Health Service Minority Biomedical Research Support Program: Grant Number S06 RR08049;
Walter H. Pattillo, Jr., Project Director; Robert A. Izydore/John A. Myers, Co principal Investigators;
sub project on the University grant titled "Synthesis of Pharmacologically Active Compounds from cis
Diacyl Diimides and Oxazolium 5 Oxides”; $70,000/year plus indirect costs; 6/1/80 12/31/83.

Public Health Service Minority Biomedical Research Support Program: Grant Number S06 RR08049;
Walter H. Pattillo, Jr., Project Director; Robert A. Izydore/John A. Myers, Co principal Investigators;
sub project on the University grant titled "Synthesis of Nitrogen Heterocycles for Evaluation as
Pharmacologically Active Agents", $85,000/year plus indirect costs; 1/1/84 12/31/87.

Glaxo Inc.; Robert A. Izydore, Principal Investigator; "Synthesis of Cyclic Hydroxamates and Cyclic
Hydrazides as Hypolipidemic Agents", $19,000 in direct costs plus $5,000 in indirect costs;
6/1/87 5/31/88.

Public Health Service Minority Biomedical Research Support Program: Grant Number S06 RR08049;
Walter H. Pattillo, Jr., Project Director; Robert A. Izydore, Principal Investigator; subproject on the
University grant titled "Synthesis of Hydroxamates and Hydrazides as Antitumor Agents", $51,182 in
first year, $206,000 for the four year period plus indirect costs; 1/1/88 12/31/91; Administrative
extension, $66,700 plus indirect costs; 1/1/92 12/31/92; administrative extension, $33,000;
1/1/93 12/31/93.

Public Health Service Minority Biomedical Research Support Program: Grant Number SO6 RR08049;
Goldie Byrd Project Director; Robert A. Izydore. Principal Investigator; subproject on the University
grant titled "Synthesis of Hydroxamates and Hydrazides as Pharmacologically Active Agents", $136,796
in first year, $490,000 for the four year period plus indirect costs; 1/1/94-12/31/97.

Public Health Service Minority Biomedical Research Support Program: Grant Number SO6 RR08049;
Byrd Project Director; Robert A. Izydore. Principal Investigator; Supplemental Funding to purchase a
Hewlett Packard GC-MS system; $53,000; March, 1995.

Office of Naval Research; Robert A. Izydore, Principal Investigator; "Request for Nuclear Magnetic
Resonance Instrumentation for North Carolina Central University", $243,058; 9/1/95-8/31/96.

Public Health Service Minority Biomedical Research Support Program: Grant Number SO6 RR08049;
Goldie Byrd Project Director; Robert A. Izydore. Principal Investigator; subproject on the University
grant titled "Synthesis of Pharmacologically Active Nitrogen Heterocycles", $131,790 in first year,
$541,853 for the four-year period plus indirect costs: 1/1/98-12/31/01.

DURHAM EAGLE